Bristol’s Baraclude Beats Hepsera In Two-year Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Potent rival Viread aims to shake up hepatitis B market.
You may also be interested in...
As It Prepares for a Future with Wyeth, Pfizer Reports Ho-Hum Q1 Results
Pfizer’s first-quarter results were down, but in line with the company’s and Wall Street’s expectations.
Gilead Gets Positive Recommendation From EU Committee To Market Viread For Hepatitis B
Company also awaits August PDUFA date for the same indication in the United States.
Baraclude Bests Hepsera On Viral Load Reduction In HBV Patients – Bristol Study
Study shows that 58 percent of Baraclude-treated patients achieved undetectable viral load at 48 weeks versus 19 percent taking adefovir.